YOLFTbeta
Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology Class A Ordinary Shares

NNNN · NASDAQ · Healthcare / Medical Instruments & Supplies

3.82USD+0.02 (+0.53%)

Price History

Full chart

Market Stats

Previous Close3.80
Open3.82
Day Range3.70 – 3.98
52-Week Range5.13 – 51.33
Volume21.84K
Market Cap267.30M
P/E (TTM)43.50
Forward P/E0.00
EPS0.14
Dividend Yield0.00%
50-Day Avg8.07
200-Day Avg20.73

About

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Michael Lau M.B.A., Ph.D.
  • Employees27
  • HeadquartersFriedrich-Ebert-Anlage 35-37, Frankfurt am Main, Germany, 60327, USA
  • Websitehttps://www.anbiobiotechnology.com

Leadership

  • Mr. Michael Lau M.B.A., Ph.D.Chief Executive Officer · b. 1982
  • Ms. Suki Song CPAChief Financial Officer · b. 1983
  • Mr. Chris TianChief Business Officer · b. 1991

Financials

Income Statement

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.43M23.54M6.71M8.19M8.65M
Growth (%)-+431.67%-71.49%+21.95%+5.64%
Cost of Revenue1.89M10.98M3.35M2.30M1.10M
Gross Profit2.54M12.56M3.36M5.89M7.54M
Gross Margin57.40%53.36%50.07%71.90%87.24%
Operating Expense86.09K2.37M1.40M3.89M1.78M
Operating Income2.46M10.20M1.96M2.00M5.77M
Operating Margin55.46%43.30%29.22%24.38%66.70%
EBITDA2.54M10.03M2.27M2.00M5.77M
EBITDA Margin57.26%42.58%33.77%24.38%66.70%
Net Income2.54M10.01M2.25M2.37M6.40M
Net Income Margin57.26%42.52%33.58%28.99%74.06%
R&D0200.00K134.70K454.23K201.31K
R&D as % of Total Revenue0.00%0.85%2.01%5.55%2.33%
Interest Expense08.00K00-
Interest Expense % of Total Revenue0.00%0.03%0.00%0.00%-

Balance Sheet

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.92M13.96M15.81M18.92M30.24M
Total Liabilities2.38M1.41M993.06K1.73M87.84K
Total Equity2.54M12.55M14.82M17.19M30.16M
Cash4.18M7.10M9.69M11.76M7.77M
Net Debt-4.18M-7.10M-9.69M-11.76M-7.77M

Cash Flow

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow4.18M4.45M898.37K2.08M-6.74M
Investing Cash Flow--1.53M1.73M337.10K-4.20M
Financing Cash Flow-0-42.84K-344.61K6.95M
Capital Expenditure02.88000
Free Cash Flow4.18M4.45M898.37K2.08M-6.74M
FCF to OCF100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateDec 31, 2024Apr 28, 2025Dec 30, 2025
EPS Estimate0.000.000.00
EPS Actual0.09-0.030.09
Surprise---
Timing---

Key Statistics & Ratios

Market Cap267.30M
Enterprise Value256.27M
Trailing P/E43.50
Forward P/E0.00
Price / Sales30.91
Price / Book8.89
EPS0.14
Book Value0.687
Revenue (TTM)8.65M
Gross Profit (TTM)7.54M
Profit Margin74.06%
Operating Margin59.09%
Return on Equity27.05%
Return on Assets14.66%
Shares Outstanding43.89M
Shares Float39.69M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
4.95%
Insiders
4.78%
Retail / Other
90.27%

Top Institutional Holders

  • Geode Capital Management, LLC
    25.76K0.06%
  • BNP Paribas Arbitrage, SA
    10.40K0.02%
  • Morgan Stanley - Brokerage Accounts
    7.34K0.02%
  • UBS Group AG
    6.34K0.01%
  • EverSource Wealth Advisors, LLC
    1870.00%
  • Wells Fargo & Co
    1000.00%
  • Bare Financial Services Inc
    150.00%
  • Ronald Blue Trust, Inc.
    00.00%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    26.74K0.06%
  • Northern Small Cap Core I
    7.14K0.02%
  • Invesco Dw Jns Islmc Glb Dev MktsETF$Acc
    350.00%